Evaluation of cinacalcet on clinical outcome depending on serum PTH level in Japanese patients with SHPT:ECO study

Evaluation of cinacalcet on clinical outcome depending on serum PTH level in Japanese patients with SHPT:ECO study - Evaluation of cinacalcet on clinical outcome for in Japanese patients with SHPT:ECO study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002769

Enrollment

120

Registered

2009-11-18

Start date

2008-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism

Interventions

administration of Cinacalcet HCl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects were eligible for the study if they met the following criteria: 1. intact PTH over 180 pg/ml and Ca over 9.0mg/dl and P over 3.5mg/dl 2. intact PTH from 60 to 180pg/ml over Ca 10.0mg/dl and P 3.5mg/dl or intact PTH from 60 to 180pg/ml over Ca 9.0mg/dl and P 6.0mg/dl

Exclusion criteria

Exclusion criteria: 1. pregnant woman 2.received therapy with bisphosphonate within 24 weeks before IC 3.received therapy with estrogen hormone when signed IC 4.severe hepatic dysfunction or cirrhosis 5. drug allergies 6. malignancy 7. unsuitable patients

Design outcomes

Primary

Measure	Time frame
the proportion of patients who achieve JSDT guideline targets	—

Countries

Japan

Contacts

Public ContactKeitaro Yokoyama

The Jikei University School of Medicine Division of Kidney and Hypertension, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026